Iscom and iscom-matrix enhance by intranasal route the IgA responses to OVA and rCTB in local and remote mucosal secretions.
Iscoms, with rCTB incorporated via the GM1 receptor, enhanced in mice the mucosal immunogenicity of rCTB as antigen after intranasal (i.n.) administration both by inducing IgA response in the remote intestinal tract mucosa and by a 100-fold increase of the specific IgA locally in the lungs. Iscom-matrix as a separate entity mixed with rCTB enhanced the rCTB-IgA response similarly. While OVA in iscoms induced high mucosal IgA responses, iscom-matrix co-administered with OVA induced low or no mucosal IgA response to OVA. A synergism between iscoms and rCTB could only be seen as an adjuvant targeting effect enhancing the IgA response to OVA in the remote genital tract mucosa. In serum, the immunomodulatory effect of iscoms after i.n. administration was seen as an enhanced serum IgG2a response.
Department of Virology, National Veterinary Institute, Biomedical Centre, Uppsala, Sweden.
J
J
Ekström
K F
KF
Hu
K L
KL
Bengtsson
B
B
Morein
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000281:Administration, Intranasal; D000818:Animals; D002772:Cholera Toxin / Q000008:administration & dosage* / Q000276:immunology; D005260:Female; D005677:G(M1) Ganglioside / Q000502:physiology; D016882:ISCOMs / Q000008:administration & dosage*; D018928:Immunity, Mucosal; D007071:Immunoglobulin A, Secretory / Q000096:biosynthesis*; D007074:Immunoglobulin G / Q000097:blood / Q000145:classification; D007279:Injections, Subcutaneous; D008168:Lung / Q000276:immunology; D051379:Mice; D010047:Ovalbumin / Q000008:administration & dosage* / Q000276:immunology; D011994:Recombinant Proteins / Q000008:administration & dosage
D000276:Adjuvants, Immunologic; D016882:ISCOMs; D007071:Immunoglobulin A, Secretory; D007074:Immunoglobulin G; D011994:Recombinant Proteins; D005677:G(M1) Ganglioside; D010047:Ovalbumin; D002772:Cholera Toxin